ENTO

$0.00

(

0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Entero Therapeutics, Inc.

NASDAQ | ENTO

4.09

USD

$0.00

(

0.00%

)

At Close (As of Oct 24, 2025)

$9.26M

Market Cap

-

P/E Ratio

-11.97

EPS

$5.84

52 Week High

$0.96

52 Week Low

HEALTHCARE

Sector

ENTO Chart

Recent Chart
Price Action

ENTO Technicals

Tags:

ENTO Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -
Total Revenue $0
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$16K
Selling General And Administrative $15K
Research And Development $904
Operating Expenses $16K
Investment Income Net -
Net Interest Income $875
Interest Income -
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $49K
Income Before Tax -$16K
Income Tax Expense $0
Interest And Debt Expense -
Net Income From Continuing Operations -$16M
Comprehensive Income Net Of Tax -
Ebit -$65K
Ebitda -$16K
Net Income -$18M

Revenue & Profitability

Earnings Performance

ENTO Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $85M
Total Current Assets $83M
Cash And Cash Equivalents At Carrying Value $163K
Cash And Short Term Investments $163K
Inventory -
Current Net Receivables -
Total Non Current Assets $1.9M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill $1.7M
Investments -
Long Term Investments -
Short Term Investments -
Other Current Assets $83M
Other Non Current Assets -
Total Liabilities $28M
Total Current Liabilities $28M
Current Accounts Payable $3M
Deferred Revenue -
Current Debt -
Short Term Debt $163K
Total Non Current Liabilities $59K
Capital Lease Obligations $141K
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $141K
Other Current Liabilities $24M
Other Non Current Liabilities -
Total Shareholder Equity $58M
Treasury Stock -
Retained Earnings -$202M
Common Stock $475
Common Stock Shares Outstanding $3.4M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$9.2M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $49K
Capital Expenditures $0
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment $88K
Cashflow From Financing $5.6M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$18M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -
Total Revenue $0
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$16K
Selling General And Administrative $15K
Research And Development $904
Operating Expenses $16K
Investment Income Net -
Net Interest Income $875
Interest Income -
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $49K
Income Before Tax -$16K
Income Tax Expense $0
Interest And Debt Expense -
Net Income From Continuing Operations -$16M
Comprehensive Income Net Of Tax -
Ebit -$65K
Ebitda -$16K
Net Income -$18M

ENTO News

ENTO Profile

Entero Therapeutics, Inc. Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Entero Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Boca Raton, Florida, focused on advancing innovative, orally administered therapies to address unmet needs in gastrointestinal diseases. Leveraging its proprietary technology platform, Entero aims to develop targeted treatments that improve patient outcomes and enhance quality of life. With a commitment to scientific excellence and patient-centered solutions, the company is poised to make significant contributions to the field of gastrointestinal health.

WGRX
+206.52%
$1.23
BYND
-9.57%
$2.56
TOVX
+95.58%
$0.66
YYAI
-15.09%
$0.07
VIVK
+49.53%
$0.38
CGBS
-39.47%
$0.03
INTC
+1.36%
$38.68
F
+10.29%
$13.61
YDKG
-16.29%
$0.06
VHAI
0.00%
$0.00
DVLT
+50.44%
$3.38
BURU
-5.27%
$0.34
BITF
+5.71%
$4.16
IONZ
-14.59%
$3.98
NEUP
+49.62%
$6.06
ADTX
-5.55%
$0.28
AXDX
-61.36%
$0.03
AAL
+8.01%
$13.79
NVDA
+1.66%
$185.18
PLUG
-1.36%
$2.88
ABEV
+0.45%
$2.21
TSLA
-3.02%
$435.40
RGTI
+2.39%
$40.54
RIG
+1.79%
$3.96
VZ
-3.51%
$38.40
SCNX
-34.80%
$1.69
QLGN
+6.53%
$3.76
AMD
+7.17%
$251.84
QBTS
+6.73%
$33.15
JOBY
+1.29%
$15.67
DNN
+2.32%
$2.79
NOK
+1.54%
$6.26
RMBL
+60.50%
$3.21
ADD
-25.47%
$0.05
ONDS
+9.06%
$7.70
WTO
-9.03%
$0.06
SRM
+53.27%
$10.30
SOFI
+3.93%
$29.18
T
+1.96%
$25.10
ADAP
-4.14%
$0.06
RF
+1.34%
$24.42
CAN
+6.22%
$1.86
NUAI
+43.86%
$5.68
LAES
+16.68%
$6.67
CIFR
+18.52%
$20.45
CUTR
-10.19%
$0.09
AIRE
-15.81%
$0.83
WLGS
-5.57%
$0.04
QS
+13.01%
$16.56
ETHD
-0.62%
$3.94
GPUS
+0.93%
$0.38
ETWO
0.00%
$3.30
ACHR
+3.75%
$11.32
NIO
+1.37%
$6.98
ASST
+6.45%
$0.92
NVTS
+4.97%
$14.28
AMC
-1.46%
$2.68
TLRY
+1.68%
$1.50
CLOV
+18.90%
$3.80
AFMD
-34.94%
$0.18
QUBT
+1.69%
$16.21
RR
+11.45%
$6.04
IREN
+8.57%
$60.65
PLTR
+2.77%
$185.49
GRAB
+2.06%
$5.83
KDLY
+10.41%
$0.79
SNAP
+0.50%
$7.91
PCG
-1.68%
$16.30
PBR
+0.08%
$11.85
BTBT
+6.85%
$3.97
OPI
-16.97%
$0.20
BULL
+2.30%
$11.08
RXRX
+1.65%
$5.82
RGTZ
-4.19%
$14.27
KLG
-9.05%
$13.35
AMZN
+1.62%
$224.69
GNTA
+90.71%
$6.16
AAPL
+1.52%
$263.52
GRYP
-10.38%
$1.38
BBD
-0.10%
$3.34
MODV
-25.22%
$0.43
IONQ
+3.96%
$61.72
UUUU
-0.11%
$21.23
MARA
+1.90%
$19.58
NRXS
-5.26%
$3.61
APLD
+2.93%
$34.36
BTG
-0.19%
$5.22
BAC
+1.56%
$52.56
LAZR
+23.66%
$2.09
WULF
+7.33%
$13.82
WU
+10.24%
$8.97
HOOD
+3.41%
$138.91
SMR
+1.38%
$38.07
DFLI
+12.38%
$1.27
RVPH
+16.12%
$0.65
XFOR
+27.50%
$3.94
BMNR
+2.29%
$50.31
PFE
+0.33%
$24.75
GOOGL
+3.14%
$261.05
UAMY
-10.52%
$11.73
WGRX
+206.52%
$1.23
BYND
-9.57%
$2.56
TOVX
+95.58%
$0.66
YYAI
-15.09%
$0.07
VIVK
+49.53%
$0.38
CGBS
-39.47%
$0.03
INTC
+1.36%
$38.68
F
+10.29%
$13.61
YDKG
-16.29%
$0.06
VHAI
0.00%
$0.00
DVLT
+50.44%
$3.38
BURU
-5.27%
$0.34
BITF
+5.71%
$4.16
IONZ
-14.59%
$3.98
NEUP
+49.62%
$6.06
ADTX
-5.55%
$0.28
AXDX
-61.36%
$0.03
AAL
+8.01%
$13.79
NVDA
+1.66%
$185.18
PLUG
-1.36%
$2.88
ABEV
+0.45%
$2.21
TSLA
-3.02%
$435.40
RGTI
+2.39%
$40.54
RIG
+1.79%
$3.96
VZ
-3.51%
$38.40
SCNX
-34.80%
$1.69
QLGN
+6.53%
$3.76
AMD
+7.17%
$251.84
QBTS
+6.73%
$33.15
JOBY
+1.29%
$15.67
DNN
+2.32%
$2.79
NOK
+1.54%
$6.26
RMBL
+60.50%
$3.21
ADD
-25.47%
$0.05
ONDS
+9.06%
$7.70
WTO
-9.03%
$0.06
SRM
+53.27%
$10.30
SOFI
+3.93%
$29.18
T
+1.96%
$25.10
ADAP
-4.14%
$0.06
RF
+1.34%
$24.42
CAN
+6.22%
$1.86
NUAI
+43.86%
$5.68
LAES
+16.68%
$6.67
CIFR
+18.52%
$20.45
CUTR
-10.19%
$0.09
AIRE
-15.81%
$0.83
WLGS
-5.57%
$0.04
QS
+13.01%
$16.56
ETHD
-0.62%
$3.94
GPUS
+0.93%
$0.38
ETWO
0.00%
$3.30
ACHR
+3.75%
$11.32
NIO
+1.37%
$6.98
ASST
+6.45%
$0.92
NVTS
+4.97%
$14.28
AMC
-1.46%
$2.68
TLRY
+1.68%
$1.50
CLOV
+18.90%
$3.80
AFMD
-34.94%
$0.18
QUBT
+1.69%
$16.21
RR
+11.45%
$6.04
IREN
+8.57%
$60.65
PLTR
+2.77%
$185.49
GRAB
+2.06%
$5.83
KDLY
+10.41%
$0.79
SNAP
+0.50%
$7.91
PCG
-1.68%
$16.30
PBR
+0.08%
$11.85
BTBT
+6.85%
$3.97
OPI
-16.97%
$0.20
BULL
+2.30%
$11.08
RXRX
+1.65%
$5.82
RGTZ
-4.19%
$14.27
KLG
-9.05%
$13.35
AMZN
+1.62%
$224.69
GNTA
+90.71%
$6.16
AAPL
+1.52%
$263.52
GRYP
-10.38%
$1.38
BBD
-0.10%
$3.34
MODV
-25.22%
$0.43
IONQ
+3.96%
$61.72
UUUU
-0.11%
$21.23
MARA
+1.90%
$19.58
NRXS
-5.26%
$3.61
APLD
+2.93%
$34.36
BTG
-0.19%
$5.22
BAC
+1.56%
$52.56
LAZR
+23.66%
$2.09
WULF
+7.33%
$13.82
WU
+10.24%
$8.97
HOOD
+3.41%
$138.91
SMR
+1.38%
$38.07
DFLI
+12.38%
$1.27
RVPH
+16.12%
$0.65
XFOR
+27.50%
$3.94
BMNR
+2.29%
$50.31
PFE
+0.33%
$24.75
GOOGL
+3.14%
$261.05
UAMY
-10.52%
$11.73
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.